Milestone Pharmaceuticals operates within the competitive biopharmaceutical and cardiovascular therapeutics landscape, competing against various pharmaceutical giants and specialized biotechnology firms developing treatments for heart arrhythmias and related conditions. In the realm of managing paroxysmal supraventricular tachycardia and atrial fibrillation, its competitors include companies that produce traditional anti-arrhythmic medications, calcium channel blockers, beta-blockers, and companies offering medical technology devices such as catheter ablation tools. While traditional interventions often require clinical administration, intravenous delivery, or invasive surgical procedures, Milestone aims to differentiate its therapeutic candidates through rapid-response, self-administered nasal delivery systems. Competing firms range from large multinational pharmaceutical corporations with expansive commercial portfolios to nimble biotech enterprises focusing on cardiovascular innovations.